Search

Your search keyword '"Nahass, Ronald G."' showing total 169 results

Search Constraints

Start Over You searched for: Author "Nahass, Ronald G." Remove constraint Author: "Nahass, Ronald G."
169 results on '"Nahass, Ronald G."'

Search Results

1. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

2. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment

3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

4. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

5. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

10. Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

13. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

17. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

19. Successful Treatment of Cutibacterium acnes Prosthetic Joint Infection With Single-Stage Exchange and Oral Antibiotics.

26. The infectious disease service line: next frontier in hospital/physician co-management?

27. Linkage to care for suburban heroin users with hepatitis C virus infection, New Jersey, USA

30. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.

31. Remdesivir for 5 or 10 Days in Patients With Severe Covid-19

32. LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

34. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

40. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

41. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.

43. How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists

45. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection

48. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

50. How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists.

Catalog

Books, media, physical & digital resources